Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.55 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.55 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | HRH1 | P35367 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29371176 | 0.89 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GALDH1A1HRH1 | |
| SCHEMBL127882 | 0.89 | EHMT2 (0.59) | EHMT2EHMT1APOBEC3GALDH1A1HRH1 | |
| Hydrochloric Acid SCHEMBL957295 | 0.87 | EHMT2 (0.57) | EHMT2EHMT1APOBEC3GALDH1A1HRH1 | |
| Hydrochloric Acid SCHEMBL3416002 | 0.87 | EHMT2 (0.57) | EHMT2EHMT1APOBEC3GALDH1A1HRH1 | |
| Hydrochloric Acid SCHEMBL476479 | 0.87 | EHMT2 (0.57) | EHMT2EHMT1APOBEC3GALDH1A1HRH1 | |
| Hydrochloric Acid SCHEMBL29421834 | 0.87 | EHMT2 (0.57) | EHMT2EHMT1APOBEC3GALDH1A1HRH1 | |
| Cysteamine SCHEMBL2637878 | 0.81 | EHMT2 (0.50) | EHMT2EHMT1APOBEC3GALDH1A1HRH1 | |
| SCHEMBL10802711 | 0.79 | EHMT2 (0.55) | EHMT2EHMT1APOBEC3GALDH1A1HRH1 | |
| SCHEMBL3736785 | 0.78 | ALDH1A1 (0.69) | EHMT2EHMT1APOBEC3GALDH1A1KMT2A | |
| SCHEMBL3991936 | 0.77 | EHMT2 (0.53) | EHMT2EHMT1APOBEC3GALDH1A1HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | LONZA SALES AG (CH) | 2026-01-29 | — | — | US | disclosed |
| US-20250382613-A1 | METHODS OF USING EXTRACELLULAR VESICLE-ASO TARGETING STAT6 | LONZA SALES AG (CH) | 2025-12-18 | — | — | US | disclosed |
| EP-4562156-A2 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | Lonza Sales AG (CH) | 2025-06-04 | — | — | EP | disclosed |
| CN-114728078-B | Extracellular vesicles linked to molecules and uses thereof | 隆萨销售股份公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-4547259-A2 | METHODS OF USING EXTRACELLULAR VESICLE-ASO TARGETING STAT6 | Lonza Sales AG (CH) | 2025-05-07 | — | — | EP | disclosed |
| CN-119948163-A | CEBP/beta targeted extracellular vesicle-ASO constructs | 隆萨销售股份有限公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119855597-A | Methods of using STAT 6-targeted extracellular vesicles-ASOs | 隆萨销售股份有限公司 | 2025-04-18 | — | — | CN | disclosed |
| US-20250115904-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | LONZA SALES AG (CH) | 2025-04-10 | — | — | US | disclosed |
| EP-4470619-A2 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | Lonza Sales AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| US-20240254481-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | LONZA SALES AG (CH) | 2024-08-01 | — | — | US | disclosed |
| US-20130217754-A1 | PREVENTIVE OR THERAPEUTIC AGENT FOR FIBROSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| EP-2628798-A1 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR FIBROSIS | Mie University (JP) | 2013-08-21 | — | — | EP | disclosed |
| US-20110111501-A1 | COMPLEX OF POLYSACCHARIDE AND DOUBLE-STRANDED RNA | NAPA JENOMICS CO., LTD. (JP) | 2011-05-12 | — | — | US | disclosed |
| US-20110034545-A1 | DOUBLE-STRANDED LIPID-MODIFIED RNA HAVING HIGH RNA INTERFERENCE EFFECT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-02-10 | — | — | US | disclosed |
| EP-2264167-A1 | DOUBLE-STRANDED LIPID-MODIFIED RNA HAVING HIGH RNA INTERFERENCE EFFECT | National Institute of Advanced Industrial Science and Technology (JP) | 2010-12-22 | — | — | EP | disclosed |
| US-20100298411-A1 | LIPID-MODIFIED DOUBLE-STRANDED RNA HAVING POTENT RNA INTERFERENCE EFFECT | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY | 2010-11-25 | — | — | US | disclosed |
| EP-2226384-A1 | COMPLEX OF POLYSACCHARIDE AND DOUBLE-STRANDED RNA | National Institute of Advanced Industrial Science and Technology (JP) | 2010-09-08 | — | — | EP | disclosed |
| EP-2217284-A2 | LIPID-MODIFIED DOUBLE-STRANDED RNA HAVING POTENT RNA INTERFERENCE EFFECT | National Institute of Advanced Industrial Science And Technology (JP) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009054551-A2 | LIPID-MODIFIED DOUBLE-STRANDED RNA HAVING POTENT RNA INTERFERENCE EFFECT | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2009-04-30 | — | — | WO | disclosed |
| EP-1731615-A1 | CYTOPLASMIC LOCALIZATION DNA AND RNA | National Institute of Advanced Industrial Science and Technology (JP) | 2006-12-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250115904-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING STAT6 | STAT6, STAT1, STAT5B | EHMT2 487/4885EHMT1 468/4885APOBEC3G 2105/4885 |
| US-20250382613-A1 | METHODS OF USING EXTRACELLULAR VESICLE-ASO TARGETING STAT6 | STAT6, EXOSC5, STAT5B | EHMT2 471/4885EHMT1 660/4885APOBEC3G 1963/4885 |
| US-20260027147-A1 | EXTRACELLULAR VESICLE-ASO CONSTRUCTS TARGETING CEBP/BETA | CEBPZ, OSBP, DIS3 | EHMT2 2828/4885EHMT1 2611/4885APOBEC3G 2537/4885 |
| US-20100298411-A1 | LIPID-MODIFIED DOUBLE-STRANDED RNA HAVING POTENT RNA INTERFERENCE EFFECT | NSUN3, NSUN2, RNASE1 | EHMT2 807/4885EHMT1 1349/4885APOBEC3G 877/4885 |
| US-20110034545-A1 | DOUBLE-STRANDED LIPID-MODIFIED RNA HAVING HIGH RNA INTERFERENCE EFFECT | NSUN3, NSUN2, ADAR | EHMT2 762/4885EHMT1 1341/4885APOBEC3G 813/4885 |
| US-20110111501-A1 | COMPLEX OF POLYSACCHARIDE AND DOUBLE-STRANDED RNA | RNGTT, MAN2A1, ADAR | EHMT2 3752/4885EHMT1 3749/4885APOBEC3G 1102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.